Franek, Edward
Pais, Prem
Basile, Jan
Nicolay, Claudia
Raha, Sohini
Hickey, Ana
Ahmad, Nadia N.
Konig, Manige
Kan, Hong
Gerstein, Hertzel C.
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 28 November 2022
Accepted: 27 January 2023
First Online: 10 March 2023
Declarations
:
: The REWIND protocol was approved by research ethics boards for all sites. All participants provided written informed consent. The trial was carefully monitored by members of an independent data monitoring committee who reviewed accruing and unblinded data every 6 months.
: Not applicable.
: EF has acted as an advisor to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Polfa Tarchomin, and reports honoraria for speaking from AstraZeneca, Bioton, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Polfa Tarchomin, Sanofi, and Servier. PP discloses no conflicts of interest. JB declares research grants from Eli Lilly and Company, ReCor, and Ablative Solutions; and consultant fees from Medtronic and Up-to-Date. CN, SR, AH, NNA, MK, and HK are employees and shareholders of Eli Lilly and Company. HCG holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He reports research grants from Eli Lilly and Company, AstraZeneca, Merck, Novo Nordisk, and Sanofi; honoraria for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, DKSH, Zuellig, Sanofi, Jiangsu Hanson, and Carbon Brand; and consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Sanofi, Kowa, Pfizer, Hanmi and Viatris.